Purvalanol A.结构式
|
常用名 | Purvalanol A. | 英文名 | Purvalanol A |
---|---|---|---|---|
CAS号 | 212844-53-6 | 分子量 | 388.894 | |
密度 | 1.3±0.1 g/cm3 | 沸点 | 590.5±60.0 °C at 760 mmHg | |
分子式 | C19H25ClN6O | 熔点 | N/A | |
MSDS | 中文版 美版 | 闪点 | 310.9±32.9 °C |
Purvalanol A.用途Purvalanol A 是一种有效的 CDK 抑制剂,对 cdc2-cyclin B,cdc2-cyclin B,cdk2-cyclin E,cdk4-cyclin D1 和 cdk5-p35 的 IC50 值分别为 4,70,35,850 和 75 nM。 |
中文名 | Purvalanol A. |
---|---|
英文名 | purvalanol A |
英文别名 | 更多 |
描述 | Purvalanol A 是一种有效的 CDK 抑制剂,对 cdc2-cyclin B,cdc2-cyclin B,cdk2-cyclin E,cdk4-cyclin D1 和 cdk5-p35 的 IC50 值分别为 4,70,35,850 和 75 nM。 |
---|---|
相关类别 | |
靶点 |
cdc2-cyclin B:4 nM (IC50) cdk2-cyclin E:35 nM (IC50) cdk2-cyclin A:70 nM (IC50) cdk4-cyclin D1:850 nM (IC50) cdk5-p35:75 nM (IC50) erk1:9000 nM (IC50) |
体外研究 | Purvalanol A抑制cdc28(酿酒酵母)和erk1,IC50为80和9000 nM。 Purvalanol A显示出针对60个人肿瘤细胞系的NCI组的抑制活性,平均GI50为2μM;两种细胞系对purvalanol A的敏感性增加~20倍:GI12为76 nM的KM12结肠癌细胞系和NCI-H522非小细胞肺癌细胞系,GI50为347 nM [1] 。 Purvalanol A是CDK2的2.5倍强效抑制剂,但在低微摩尔范围内也有效抑制DYRK1A和许多其他蛋白激酶。 Purvalanol A抑制MKK1,MAPK2/ERK2,JNK/SAPK1c,IC50分别为80,26,84μM[2]。 Purvalanol A选择性地抑制细胞蛋白的磷酸化。 Purvalanol A可防止血清诱导的G1期进展过程中细胞周期蛋白D和E含量的增加。 Purvalanol A在无细胞条件下不抑制转录[3]。 |
参考文献 |
密度 | 1.3±0.1 g/cm3 |
---|---|
沸点 | 590.5±60.0 °C at 760 mmHg |
分子式 | C19H25ClN6O |
分子量 | 388.894 |
闪点 | 310.9±32.9 °C |
精确质量 | 388.177826 |
PSA | 87.89000 |
LogP | 2.77 |
外观性状 | 粉末 |
蒸汽压 | 0.0±1.7 mmHg at 25°C |
折射率 | 1.654 |
储存条件 | −20°C |
水溶解性 | methylene chloride: 50 mg/mL, clear, colorless |
个人防护装备 | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
---|---|
危险品运输编码 | NONH for all modes of transport |
WGK德国 | 3 |
海关编码 | 2933990090 |
海关编码 | 2933990090 |
---|---|
中文概述 | 2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0% |
申报要素 | 品名, 成分含量, 用途, 乌洛托品请注明外观, 6-己内酰胺请注明外观, 签约日期 |
Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Phosphoproteomic Analysis of Aurora Kinase Inhibition in Monopolar Cytokinesis.
J. Proteome Res. 14 , 4087-98, (2015) Cytokinesis is the last step of the cell cycle that requires coordinated activities of the microtubule cytoskeleton, actin cytoskeleton, and membrane compartments. Aurora B kinase is one of the master... |
|
Involvement of atypical transcription factor E2F8 in the polyploidization during mouse and human decidualization.
Cell Cycle 14 , 1842-58, (2015) Polyploid decidual cells are specifically differentiated cells during mouse uterine decidualization. However, little is known about the regulatory mechanism and physiological significance of polyploid... |
|
KAP regulates ROCK2 and Cdk2 in an RNA-activated glioblastoma invasion pathway.
Oncogene 34(11) , 1432-41, (2015) Aberrant splicing of the cyclin-dependent kinase-associated phosphatase, KAP, promotes glioblastoma invasion in a Cdc2-dependent manner. However, the mechanism by which this occurs is unknown. Here we... |
P01 |
2-(1R-Isopropyl-2-hydroxyethylamino)-6-(3-chloroanilino)-9-isopropylpurine NG-60 |
(2R)-2-[[6-(3-chloroanilino)-9-propan-2-ylpurin-2-yl]amino]-3-methylbutan-1-ol |
NG-60 |
(2R)-2-({6-[(3-Chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methyl-1-butanol |
(2R)-2-({6-[(3-Chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methylbutan-1-ol |
1-Butanol, 2-[[6-[(3-chlorophenyl)amino]-9-(1-methylethyl)-9H-purin-2-yl]amino]-3-methyl-, (2R)- |
Purvalanol A |
Purv |